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Background: The large individual variability in response to drugs for smoking cessation
suggests that speciﬁc treatments can be more effective in particular subgroups of smokers.
In the context of personalized medicine, the main aim of the present study was to evaluate
whether the CHRNA4 and CHRNB2 polymorphisms are associated with response to
smoking cessation therapies in patients from a smoker assistance program.
Methods:This cohort study enrolled 483 smoking patients who received behavioral coun-
seling and drug treatment (varenicline, bupropion, and/or nicotine replacement therapy).
Smoking cessation success was considered for patients who completed 6 months of con-
tinuous abstinence. Fagerström test for nicotine dependence (FTND) and Issa situational
smoking scores were analyzed for nicotine dependence. The CHRNA4 (rs1044396 and
rs2236196) and CHRNB2 (rs2072660 and rs2072661) polymorphisms were genotyped by
high resolution melting analysis.
Results: Patients with rs1044396 CC genotype had lower success rate in treatment with
varenicline (29.5%) compared with carriers of CT or TT genotypes (50.9%; p = 0.007,
n = 167). The CT or TT genotypes were associated with higher odds ratio for success
(OR = 1.67, 95% CI = 1.10–2.53, p = 0.02), in a multivariate model. We did not observe
signiﬁcant differences in the FTNDand Issa scores according to the studied polymorphisms.
Conclusion:The CHRNA4 rs1044396 is associated with smoking cessation in individuals
on varenicline therapy. We suggest that this polymorphism inﬂuences the varenicline
response, but replications of this ﬁnding are needed.
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INTRODUCTION
Smoking is one of the most important risk factors associated
with the development of cardiovascular and respiratory diseases,
besides being considered a leading cause of cancer death (MacLean
and Chockalingam, 1999; Pappas et al., 2007; Oliveira et al., 2008;
Roger et al., 2012; Jairam et al., 2013). Data showed that current
smokers have an increased cardiovascular risk compared to former
smokers even in subjects with a long and intense smoking history
(Jairam et al., 2013). A current epidemiological study, involving
187 countries, reported a moderate reduction in the prevalence of
smoking at the global level. Nevertheless, the number of smokers
signiﬁcantly increased from 721 million in 1980 to 967 million in
2012 (Ng et al., 2014).
Many smokers are aware of these harmful effects. However,
only 4–7% of smokers are able to quit smoking without medi-
cation or formal treatment (Fiore et al., 2008; Centers for Disease
Control andPrevention (CDC),2010). First line drugs for smoking
cessation approved by the FDA (US Food and Drug Administra-
tion) include nicotine replacement therapy (NRT), bupropion (a
norepinephrine-dopamine reuptake inhibitor), and varenicline (a
partial α4 and β2 agonist subunits of the nicotinic acetylcholine
receptors). Varenicline has the greatest therapeutic efﬁcacy in the
smoking cessation process (Fiore et al., 2000, 2008).
The large individual variability in response to drugs for
smoking cessation suggests that the treatment can be more
effective in speciﬁc subgroups of smokers (Lerman et al., 2004;
Swan and Lessov-Schlaggar, 2009; Quaak et al., 2014). In this
way, the understanding of the factors that are involved in
nicotine dependence (ND) and in the smoking cessation pro-
cess is required to optimize this treatment. Studies demon-
strated that genetic factors account for approximately 50% of
the variance in smoking cessation success (Xian et al., 2003;
Quaak et al., 2014). Also, these factors are less well known than
the genetic factors that inﬂuence nicotine dependence (Xian
et al., 2003; Lessov et al., 2004; Broms et al., 2006; King et al.,
2012).
Several genetic association studies showed that polymorphisms
in the CHRNA4 and CHRNB2 genes were associated with smok-
ing initiation, ND, as well as with smoking cessation (Feng et al.,
2004; Li et al., 2005; Ehringer et al., 2007; Hutchison et al., 2007;
Conti et al., 2008; Breitling et al., 2009; Wessel et al., 2010; Chu
et al., 2011; Han et al., 2011; King et al., 2012; Swan et al., 2012;
Wei et al., 2012; Kamens et al., 2013). However, there are some
phenotypes with controversial ﬁndings in the literature. The
CHRNA4 and CHRNB2 encode the α4 and β2 subunits of the
nicotinic acetylcholine receptors (nAChRs) which are the most
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abundant subunits in the brain and speciﬁc targets of the vareni-
cline action (Zoli et al., 1998; Hogg et al., 2003; Coe et al., 2005).
The α4 and β2 subunits are important targets of the nicotine
action because the α4β2 nAChR are necessary and sufﬁcient
for nicotine reward, tolerance, and sensitization (Tapper et al.,
2004).
In this context of personalized medicine, the main aim of the
present study was to evaluate whether the CHRNA4 and CHRNB2
polymorphisms are associated with response to smoking cessation
therapies in patients from a smoking assistance program.
MATERIALS AND METHODS
PATIENT SAMPLE
This cohort study enrolled 483 smoking patients from the PAF
(Programa de Assistência ao Fumante/Smoker Assistance Pro-
gram), Heart Institute (InCor), University of Sao Paulo Medical
School, Sao Paulo, Brazil, between January, 2007 and September,
2013. The study protocol was approved by the Institutional Ethics
Committee (0022/11).
The drug treatment consisted of an initial medical visit plus
an average of four follow-up medical visits for 12 weeks. The
follow-up was made by phone in patients who did not continue
to come on scheduled medical visits. Clinical data and carbon
monoxide concentration were collected in all visits. Demographic,
socio-economic, and clinical data were acquired. Patients received
behavioral counseling and drug treatment from physicians spe-
cialized in smoking cessation. Arbitrarily, bupropion plus NRT
was prescribed for patients who smoked less than one cigarette
pack per day; while varenicline was prescribed for patients who
smoked one or more cigarette pack(s) per day, or who failed
in previous attempts with bupropion plus NRT. Our indication
to start the co-administration of bupropion and varenicline was
if the patient did not achieve complete abstinence after 2 or
3 weeks of starting varenicline use, or if the patient achieved
complete abstinent, but presented moderate, or intense discom-
fort abstinence symptoms. Continuous abstinence rate (CAR)
was investigated after 6 months as of starting pharmacother-
apy. Smoking status (outcome) was divided into: success group
(patients who completed 6 months of CAR conﬁrmed by carbon
monoxide concentration), relapse group (patients who did not
complete 6 months of CAR), and resistant group (patients who
never achieved CAR after starting drug treatment; Issa et al., 2013,
2014).
We analyzed the Fagerström test for nicotine dependence
(FTND) and Issa situational smoking score (Issa score). The
FTND, a revised version of the Fagerström tolerance ques-
tionnaire, comprises six questions (ranging from 0 to 10
points) and the patients are grouped into ﬁve categories: 1–2
points = very low dependence; 3–4 points = low dependence;
5 points = medium dependence; 6–7 points = high depen-
dence; and 8–10 points = very high dependence. The FTND is
used in many countries as a cheap, non-invasive and easy way to
assess ND (Fagerstrom et al., 1990). The Issa score comprises four
questions (ranging from 0 to 4 points) with one point for each
afﬁrmative response. This score is based on psychoactive effects
of nicotine in the process of cognition, attention, concentration,
mood, well-being, and pleasure (Issa, 2012).
GENOTYPING
Genomic DNA from subjects was extracted from peripheral
blood following a standard salting-out procedure. Supplementary
Figure S1 shows genotyping detected by polymerase chain reac-
tion (PCR) followed by high resolution melting (HRM) analysis
with the Rotor Gene 6000® instrument (Qiagen, Courtaboeuf,
France). The QIAgility® (Qiagen, Courtaboeuf, France), an auto-
mated instrument, was used according to instructions to optimize
the sample preparation step (Santos et al., 2011a,b). Ampliﬁca-
tions of the fragments for the CHRNA4 rs1044396 (c.C1629T),
CHRNA4 rs2236196 (c.G534A), CHRNB2 rs2072660 (c.T313C),
and CHRNB2 rs2072661 (c.G472A) polymorphism were per-
formed using the following primers sense and antisense: 5′- AGC-
CCTCTCCGTGCAAAT -3′ and 5′- CTTTGGTGCTGCGGGTCT
-3′ (84 pairs base), 5′- ACCCTCTCCTAGCGAAGCAG -3′ and 5′-
CAGGGTCCTTGAGCCTCTC -3′ (73 pairs base), 5′- AGCAAG-
GCTGCTAAGTGGAA-3′ and 5′-GACAATCCTGTCCCCTTCCT
-3′ (89 pairs base), and 5′- CTGGCCTGACACAATGGTAG -
3′ and 5′- GCTGCTGTCCACTCAAGCA -3′ (90 pairs base),
respectively. A 40-cycle PCR was carried out with the follow-
ing conditions: denaturation of the template DNA for ﬁrst cycle
of 94◦C for 120 s, denaturation of 94◦C for 20 s, annealing
(59.6◦C for the rs1044396, 56.7◦C for the other) for 20 s, and
extension of 72◦C for 22 s. PCR was performed with addition
of ﬂuorescent DNA-intercalating SYTO9® (1.5 μM; Invitro-
gen, Carlsbad, CA, USA). In the HRM phase, the Rotor Gene
6000® measured the ﬂuorescence in each 0.1◦C temperature
increase in the range of 70–88◦C. Melting curves were gener-
ated by the decrease in ﬂuorescence with the increase in the
temperature; and in analysis, nucleotide changes result in three
different curve patterns (Supplementary Figure S1). Samples
of the three observed curves were analyzed using bidirectional
sequencing as a validation procedure (ABI Terminator Sequenc-
ing Kit® and ABI 3500XL Sequencer® – Applied Biosystems,
Foster City, CA, USA; Santos et al., 2011a,b). The two meth-
ods gave identical results in all tests. The wild-type, heterozy-
gous and homozygous genotypes could be easily discernible by
HRM analysis. In addition, 6% of the samples were randomly
selected and reanalyzed as quality controls and gave identical
results.
STATISTICAL ANALYSIS
Continuous variable data are presented as mean and SD and cate-
gorical variables as frequencies. Chi-square test was performed
for the comparative analysis of categorical variables (general
characteristics, smoking status rates, and categorized nicotine
dependence scores) according to CHRNA4 and CHRNB2 poly-
morphisms. The Student’s t-test was used for comparing general
characteristics and, FTND according to CHRNA4 and CHRNB2
polymorphisms. Logistic regression univariate and multivariate
models were performed to evaluate the odds ratio (OR) for smok-
ing cessation success. In the logistic regression, we showed results
of the dominant and recessive models for the rs1044396 and for
the rs2236196, respectively, based on ﬁndings from previous stud-
ies (Li et al., 2005; Markett et al., 2011; Tsai et al., 2012). Also,
addictive models for the rs2072660 and rs2072660 were shown
based on ﬁndings from previous studies (Ehringer et al., 2007;
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Wessel et al., 2010; Swan et al., 2012). Multiple linear regression
models for FTND score were performed to evaluate the inﬂuence
of the polymorphisms plus covariates. Linkage disequilibrium,
Hardy–Weinberg equilibrium, and haplotype analysis were con-
ducted with Haploview 4.0. All statistical analyses were carried out
using SPSS software (v.16.0), with the level of signiﬁcance set at
p < 0.05.
RESULTS
GENERAL CHARACTERISTICS AND CHRNA4 AND CHRNB2
POLYMORPHISMS
Table 1 shows general and clinical characteristics according to
CHRNA4 rs1044396 polymorphism in the overall patient sample
and in patients treated with varenicline. We show the general char-
acteristics among rs1044396 genotypes because it was the only one
signiﬁcantly associatedwith smoking cessation success.We did not
ﬁnd signiﬁcant differences in the demographic and clinical data
according to overall or varenicline groups.
The frequency of the CHRNA4 rs1044396 T, CHRNA4
rs2236196 G, CHRNB2 rs2072660 T, and CHRNB2 rs2072661
A alleles were 44.1, 36.8, 28.7, and 26.7%, respectively. The
genotypic distributions for the rs1044396, rs2236196, rs2072660,
and rs2072661 polymorphisms were in accordance with Hardy–
Weinberg equilibrium (X2 = 3.18, p = 0.05, X2 = 1.12,
p = 0.29, X2 = 0.15, p = 0.70, and X2 = 0.32, p = 0.57,
respectively). Linkage disequilibrium analysis shows that the
CHRNA4 rs1044396 and rs2236196, and the CHRNB2 rs2072660
and rs2072661 are in strong disequilibrium in our popula-
tion (LD = 96, and LD = 89, n = 483; Supplementary
Figure S2).
SMOKING CESSATION SUCCESS ACCORDING TO CHRNA4 rs1044396
POLYMORPHISM
Table 2 shows smoking cessation success rates of patients accord-
ing to prescribed drugs and CHRNA4 rs1044396 polymorphism.
Patients with the CC genotype had lower success rate when in
treatment with varenicline (29.5%) compared with patients with
CT or TT genotypes (50.9%; p = 0.007, n = 167). Also, Figure 1
shows the distribution of the success, relapse, and resistance rates
according to the genotypes in patients treated with varenicline. A
signiﬁcant difference in the smoking cessation rate was observed
when separated into genotypic groups (CC = 29.5%,CT = 51.5%,
TT = 50.0%; p = 0.02). No association was observed in other
groups of drugs (varenicline plus bupropion, or bupropion plus
NRT).
Table 3 shows a logistic regression multivariate analysis for
smoking cessation success in the patient group treatedwith vareni-
cline. Patients with rs1044396 CT or TT genotypes were associated
with higher OR for success (OR = 1.67, 95% CI = 1.10–2.53,
p = 0.02), in a model including sex, age, race, and FTND score. In
a logistic regression univariate analysis, CT or TT genotypes were
associated with OR for success (OR = 2.48, 95% CI = 1.27–4.84,
p = 0.008).
In an analysis within the group of the White patients (n = 133;
HWE X2 = 2.68; HWE p-value = 0.10), we also observed the
same signiﬁcant ﬁndings. Patients with the CC genotype had
30.0% of success with varenicline treatment, while patients with
Table 1 | Demographic and clinical characteristics according to
CHRNA4 rs1044396 polymorphism.






Age (years) 52 ± 10 54 ± 23 0.27
Gender, female (%) 58.9 51.4 0.09
Self-declared race, White (%) 59.9 64.0 0.10
Scholarity, college (%) 27.2 27.4 0.55
Body mass index (Kg/m2) 27 ± 5 26 ± 5 0.06
FTND 6.9 ± 2.4 6.7 ± 2.5 0.66
FTND, ≥6 (%) 67.9 71.1 0.39
Issa score, 3 or 4 (%) 79.3 70.4 0.38
Hypertension (%) 42.6 40.2 0.61
Coronary artery disease (%) 13.0 17.4 0.20
Acute myocardial infarction (%) 16.0 19.0 0.43
Dyslipidemia (%) 43.8 36.4 0.12
Diabetes mellitus type 2 (%) 17.9 17.1 0.53
Obesity (%) 5.6 5.6 0.98
Depression (%) 19.1 20.6 0.71




Asthma (%) 2.5 1.9 0.66
Number of diagnosed diseases 2.3 ± 1.6 2.5 ± 1.7 0.43
Patients treated with






Age (years) 52 ± 9 52 ± 11 0.84
Gender, female (%) 57.3 55.7 0.41
Self-declared race, White (%) 72.7 89.4 0.01
Scholarity, college (%) 32.8 34.9 0.78
Body mass index (Kg/m2) 27 ± 4 27 ± 5 0.46
FTND 7.2 ± 2.7 6.8 ± 2.6 0.45
FTND ≥6 (%) 73.8 74.7 0.83
Hypertension (%) 31.1 26.4 0.51
Coronary artery disease (%) 8.2 10.4 0.65
Acute myocardial infarction (%) 9.8 12.3 0.63
Dyslipidemia (%) 23.0 26.4 0.62
Diabetes mellitus type 2 (%) 13.0 17.9 0.10
Obesity (%) 0.0 3.8 0.13
Depression (%) 18.0 17.9 0.99
Anxiety (%) 13.1 11.3 0.73
(Continued)
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Table 1 | Continued
Patients treated with









Asthma (%) 1.6 1.9 0.91
Number of diagnosed diseases 1.9 ± 1.5 1.8 ± 1.5 0.80
FTND, Fagerström test for nicotine dependence (range from 0 to 10 points). Issa
score, Issa situational smoking score (range from 0 to 4 points) was made for
patients with FTND score ≤4 (n = 84). Issa score was not included for the group
of patients with varenicline.
Table 2 | Smoking cessation success rate of patients according to
prescribed drugs and CHRNA4 rs1044396 polymorphism.
Success rate (%)
Patient group CC CT orTT p-value
Overall (n = 483) 37.0 46.4 0.05
Varenicline (n = 167) 29.5 50.9 0.007
Varenicline plus bupropion (n = 79) 40.0 50.0 0.41
Bupropion plus NRT (n = 237) 42.1 42.2 0.98
NRT, nicotine replacement therapy (patch and/or gum).
FIGURE 1 | Status of the patients treated with varenicline according to
CHRNA4 rs1044396 polymorphism. (A) status according to dominant
model. (B) status according to additive model.
CT or TT genotypes had 51.6% (p = 0.02). In the logistic
regression multivariate analysis, rs1044396 CT or TT genotypes
were associated with higher OR for success (OR = 1.97, 95%
CI = 1.16–3.34, p = 0.01).
Table 3 | Logistic regression multivariate analysis for smoking
cessation success in the patients submitted to varenicline therapy
(n = 167)
Variables OR 95% CI p-value
CT or TT genotypes for the CHRNA4
rs1044396
1.67 1.10–2.53 0.02
Gender (male) 1.17 0.79–1.73 0.44
Age 1.01 0.97–1.05 0.31
Self-declared race (White) 1.07 0.70–1.61 0.77
FTND Score 0.96 0.89–1.05 0.38
FTND, Fagerström test for nicotine dependence.
SMOKING CESSATION SUCCESS ACCORDING TO CHRNA4 rs2236196,
CHRNB2 rs2072660, AND CHRNB2 rs2072661 POLYMORPHISMS
Smoking cessation success rate did not show signiﬁcant differences
among rs2236196, rs2072660, and rs2072661 genotypes for all
drug groups, even in a multivariate model.
For patient group with varenicline, the OR for success was of
1.15 (95% CI = 0.61–2.17, p = 0.66) for the variable CHRNA4
rs2236196. Patients with AA, AG, or GG genotypes had 44.2, 46.3,
and 30.4% of success during the varenicline therapy (p = 0.40).
For the CHRNB2 rs2072660 and rs2072661polymorphisms, we
found ORs of 1.01 (95% CI = 0.97–1.05, p = 0.66) and 1.08 (95%
CI = 0.59–1.98, p = 0.81) for success in patients with varenicline,
respectively. Patients with rs2072660 TT, TC, or CC genotypes had
41.9%, 44.3%, and 46.2%of success during the varenicline therapy
(p = 0.94). Patients with rs2072661 GG, GA, or AA genotypes had
40.9, 46.8, and 41.7% of success during the varenicline therapy
(p = 0.76).
HAPLOTYPE ANALYSIS
The T-A haplotype for the CHRNA4 was associated with smoking
cessation success (OR = 1.33, 95% CI = 1.03–1.72, p = 0.03) in a
multivariate analysis, while no association was found for the C-G
and C-A haplotypes. For the CHRNB2 C–G, T–A, T–G, and C–
A haplotypes, no association was found with smoking cessation
success (p-values: 0.96, 0.56, 0.32, and 0.57, respectively).
FTND AND ISSA SCORES ACCORDING TO CHRNA4 AND CHRNB2
POLYMORPHISMS
We did not observe signiﬁcant differences in the FTND and Issa
scores according to rs1044396 polymorphism in the overall patient
group (Table 1). In addition, studied polymorphisms were not
associated with FTND score in multiple linear regression models
(Supplementary Table S1).
DISCUSSION
Several studies have indicated theCHRNA4 andCHRNB2 genes as
strong candidates for the understanding of genetic factors related
to ND and smoking cessation success (Li et al., 2005; Ehringer
et al., 2007; Conti et al., 2008; Breitling et al., 2009; Wessel et al.,
2010; Chu et al., 2011; King et al., 2012; Swan et al., 2012; Wei
et al., 2012; Kamens et al., 2013). In our study, the main ﬁnding
is the association of CHRNA4 rs1044396 polymorphism with the
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smoking cessation success in patients treated with varenicline. No
genetic association was identiﬁed for patients treated with bupro-
pion and NRT. Corroborating our ﬁndings, King et al. (2012) also
identiﬁed signiﬁcant association of CHRNA4 variants with vareni-
cline response, but not with bupropion. These ﬁndings might
likely occur because the CHRNA4 gene encodes receptors which
are the speciﬁc targets of varenicline action (King et al., 2012).
Probably, in this present study, we did not ﬁnd statistical differ-
ence in the success rate according to the rs1044396 among patients
treated with varenicline plus bupropion because of low statistical
power due to small sample size. Also, patients with CC genotype
treated with varenicline plus bupropion did not have low suc-
cess rate as in the case of patients with CC genotype treated with
varenicline.
We used a dominantmodel for theCHRNA4 rs1044396 accord-
ing to previous studies (Markett et al., 2011; Tsai et al., 2012). We
observed that patients treated with varenicline carrying TT or CT
genotypes had an OR of 2.18 for smoking cessation success com-
pared with patients carrying CC genotype. Even in an analysis
using only self-reported White patients, our result was signiﬁcant.
Corroborating our ﬁnding, previous studies showed the associa-
tion of the CHRNA4 rs1044396 T allele with a protective effect
in different phenotypes, such as: lower levels of depression, anxi-
ety, and emotional instability, and lower propensity for ND (Feng
et al., 2004; Breitling et al., 2009; Markett et al., 2011; Tsai et al.,
2012).
To date, there are very few studies on the pharmacogenetic of
varenicline (King et al., 2012; Swan et al., 2012). King et al. (2012)
provided evidence thatmultiple genetic loci contribute to smoking
cessation and therapeutic response. They also suggested that dif-
ferent loci are associated with varenicline vs. bupropion responses.
Swan et al. (2012) showed the association of the CHRNB2 variants
with nausea, an adverse effect which is reported to be the most
common reason for discontinuation of varenicline. They con-
cluded that further pharmacogenetic investigations are warranted.
Regarding the functional implication of the CHRNA4 rs1044396
polymorphism, it is still not well established. Winterer et al.
(2011) made a functional study for the CHRNA4 rs1044396 poly-
morphism introducing a complementary DNA with a haplotype
containing the rs1044396 intoXenopus oocytus expressing human
α4β2 nAChR. They measured the electrophysiological response of
the receptors under increasing concentration of acetylcholine and
observed that the number of α4β2 nAChRs in the high-afﬁnity
state was different among haplotypes (Winterer et al., 2011). The
high-afﬁnity state indicates generally that a relatively low concen-
tration of a ligand is sufﬁcient to fully occupy a ligand-binding
site and trigger a physiological response (Winterer et al., 2011;
Greenwood et al., 2012). Thus, we suggest that this functional
ﬁnding might be, at least partially, responsible for the association
of rs1044396 with smoking cessation success in our scenario. In
addition, the rs1044396 alleles can be in linkage disequilibrium
with haplotype blocks as reported by Feng et al. (2004; rs2273504,
rs2273502, rs1044396, rs1044397, rs3827020, and rs2236196) and
by Han et al. (2011; rs2236196, rs3787138, rs10443196, rs1044394,
and rs6010918).
Markou et al. (1998) and Paperwalla et al.’s (2004) studies
showed that depression and anxiety are both highly comorbid
with nicotine dependence. Thus, further studies could evaluate
all these different endophenotypes in an attempt to elucidate the
mechanisms by which CHRNA4 polymorphisms might modulate
psychiatric disorders, ND, and smoking cessation (Breitling et al.,
2009).
Regarding the CHRNA4 rs2236196, CHRNB2 rs2072660, and
CHRNB2 rs2072661 polymorphisms, we did not identify any
signiﬁcant association with the response to smoking cessation
therapies. A study involving 925 smokers treated with NRT from
the United Kingdom did not ﬁnd any association of the rs2236196
and rs2072660 with smoking cessation, but they also did not ﬁnd
an association of the rs1044396 with NRT response (Spruell et al.,
2012). In a clinical trial of varenicline, King et al. (2012) found a
signiﬁcant associationbetween rs2236196Gallelewith continuous
abstinence from 9 to 12 weeks. Hutchison et al. (2007) studying
smokers of European ancestry, reported that the rs2236196G allele
was associated with differential treatment response in a trial com-
paring different forms of nicotine therapy. Another study showed
associations of the rs2072660 with the abstinence rate in patients
treated with bupropion (Conti et al., 2008) and of the rs2072661
with quitting success in response to nicotine patch (Perkins et al.,
2009).
Regarding FTND and Issa scores, no signiﬁcant association
was found for the CHRNA4 or CHRNB2 studied polymorphisms.
Similarly, other studies did not ﬁnd an association between these
polymorphisms with ND (Feng et al., 2004; Li et al., 2005; Etter
et al., 2009; Han et al., 2011). However, some studies reported a
signiﬁcant association of the CHRNA4 rs1044396 and rs2236196
polymorphisms with ND. Breitling et al. (2009) showed that the
C allele for rs1044396 and G allele for rs2236196 may be associ-
ated with higher risk for ND in Germans. Li et al. (2005) showed
association of the rs2236196 with ND in African–American carri-
ers of the A allele. An interesting observation is that the minor
allele for the rs2236196 differs among ethnic groups. The G
is the minor allele in Europeans and the A is the minor allele
in African–Americans. This difference in allelic frequency may
help to explain the somehow controversial ﬁndings among eth-
nic backgrounds (Li et al., 2005). For the CHRNB2, Wessel et al.
(2010) observed association of the rs2072660 and rs2072661 with
mean of FTND score. Another interesting study provided evi-
dence on the presence of gene–gene interaction among the four
genes (CHRNA4, CHRNB2, BDNF, and NTRK2) in affecting ND
(Li et al., 2008).
There are some limitations in our study. First, our sample size
of patients treated with varenicline is relatively small and, conse-
quently, our statistical power is reduced and a spurious association
effect is possible. However, we were able to identify signiﬁcant dif-
ferences among genotypes, even including potential confounders.
Second, we were not able to evaluate the main ﬁnding in the non-
White group because of the number of patients. Our main ﬁnding
remains signiﬁcant even in an analysis of the self-reported White
patients. The self-reported race/color classiﬁcation is the most
applied in the clinical routine and some studies showed that it is
a good proxy of genetic ancestry information (Pena et al., 2011;
Soares et al., 2012). Third, the range in the FTND score is small in
this patient cohort because most of the patients who attended PAF
were classiﬁed as having moderate or strong dependency. Fourth,
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we used multivariate models with the available variables, but we
were not able to add other biological aspects or environmental
factors which could be important, such as functionality of the
receptors, depression and motivation.
In conclusion, the CHRNA4 rs1044396 is associated with
smoking cessation in varenicline therapy.We suggest that this poly-
morphism inﬂuences the varenicline response, but replications of
this ﬁnding are needed.
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